Prognostic factors of the efficiency of obtaining the autologous precursor cells of hemopoiesis for further transplantation after large-dose chemotherapy: review of literature and the authors' data
- Authors: Popov A.Y.1, Zhukov N.N.1, Minenko S.V.1, Andreyeva L.Y.1, Ptushkin V.V.1
-
Affiliations:
- Department of Adolescent and Age-Related Clinical Oncology, Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology
- Issue: No 3 (2008)
- Pages: 34-44
- Section: HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Published: 24.08.2008
- URL: https://oncohematology.abvpress.ru/ongm/article/view/723
- DOI: https://doi.org/10.17650/1818-8346-2008-0-3-34-44
- ID: 723
Cite item
Full Text
Abstract
To obtain a sufficient number of hemopoietic progenitor cells (HPCs) for a rapid and stable recovery of hematopoiesis is one of the major conditions for safe high-dose chemotherapy. The paper analyses the current approaches to mobilizing and collecting HPCs, as well as the factors influencing their efficiency. By using their own large material (264 patients who had undergone mobilizing procedures), the authors have shown that none of predictors (age, a history of multiple courses of chemotherapy, peripheral blood levels of CD34+ cells at sampling, etc.) may identify patients in whom peripheral blood HPCs cannot be certainly ineffectively collected. At the same time, combined mobilization with myelostimulating factors (granulocyte, granulocytemacrophage colony-stimulating factors) and cytostatics (high-dose cyclophosphamide) yield the greatest quantities of HPCs from peripheral blood in patients with solid tumors and multiple myeloma.
About the authors
A. Yu. Popov
Department of Adolescent and Age-Related Clinical Oncology, Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology
Author for correspondence.
Russian Federation
N. N. Zhukov
Department of Adolescent and Age-Related Clinical Oncology, Federal Research Clinical Centre of Pediatric Hematology, Oncology and ImmunologyRussian Federation
S. V. Minenko
Department of Adolescent and Age-Related Clinical Oncology, Federal Research Clinical Centre of Pediatric Hematology, Oncology and ImmunologyRussian Federation
L. Yu. Andreyeva
Department of Adolescent and Age-Related Clinical Oncology, Federal Research Clinical Centre of Pediatric Hematology, Oncology and ImmunologyRussian Federation
V. V. Ptushkin
Department of Adolescent and Age-Related Clinical Oncology, Federal Research Clinical Centre of Pediatric Hematology, Oncology and ImmunologyRussian Federation
References
Supplementary files

